A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants

Haiyan Li,1 Zhenhua Yang,1 Shuang Zhang,1 Lin Xu,1 Yudong Wei,1 Jun Jiang,2 Luzelena Caro,3 Hwa-Ping Feng,3 Jacqueline B McCrea,3 Meng Li,2 Shuang Xie,2 Jiangdian Wang,2 Xu Min Zhao,2 Shengmei Mu2 1Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People’s Republic of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/5ba2d1b73d934369bcea130b373ff7f2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5ba2d1b73d934369bcea130b373ff7f2
record_format dspace
spelling oai:doaj.org-article:5ba2d1b73d934369bcea130b373ff7f22021-12-02T12:06:34ZA Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants1179-1438https://doaj.org/article/5ba2d1b73d934369bcea130b373ff7f22020-02-01T00:00:00Zhttps://www.dovepress.com/a-single--and-multiple-dose-study-to-evaluate-the-pharmacokinetics-of--peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Haiyan Li,1 Zhenhua Yang,1 Shuang Zhang,1 Lin Xu,1 Yudong Wei,1 Jun Jiang,2 Luzelena Caro,3 Hwa-Ping Feng,3 Jacqueline B McCrea,3 Meng Li,2 Shuang Xie,2 Jiangdian Wang,2 Xu Min Zhao,2 Shengmei Mu2 1Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Infectious Diseases, MSD (China) R&D, Beijing, People’s Republic of China; 3Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, People’s Republic of ChinaTel +86 108 226 6226Email haiyanli1027@hotmail.comPurpose: The burden of hepatitis C virus infection is particularly high in Asian countries, and new treatments are urgently needed. The purpose of this study was to characterize the pharmacokinetics (PK) and safety of the fixed-dose combination tablet of elbasvir/grazoprevir in healthy Chinese participants.Patient and Methods: In this Phase I, single-site, open-label, 3-period study in healthy Chinese adults, participants received a single tablet of elbasvir 50 mg/grazoprevir 100 mg, followed by blood sampling for up to 96 hrs (http://www.chinadrugtrials.org.cn/ CTR20160034; Protocol PN071). Participants then received 1 tablet daily for 10 days, followed by a minimum 10-day washout, after which participants received a single dose of 2 tablets (elbasvir 100 mg/grazoprevir 200 mg). Elbasvir and grazoprevir PK were assessed following single and multiple doses. Safety and tolerability were also evaluated.Results: Twelve participants (50% male) were enrolled in and completed the study. Following single-dose oral administration of elbasvir 50 mg/grazoprevir 100 mg or elbasvir 100 mg/grazoprevir 200 mg, the median Tmax was 3– 4 hrs and elimination half-life was 18 hrs (elbasvir) and 30 hrs (grazoprevir). Multiple-dose administration resulted in AUC0– 24 accumulation ratios of 1.58 (elbasvir) and 2.35 (grazoprevir). Both elbasvir 50 mg/grazoprevir 100 mg and 100 mg/200 mg regimens were generally well tolerated.Conclusion: Single-dose administration of elbasvir 50 mg/grazoprevir 100 mg or 100 mg/200 mg and once-daily administration of elbasvir 50 mg/grazoprevir 100 mg for 10 days has been adequately characterized, with PK values within the expected range, and was generally well tolerated in healthy Chinese male and female participants.Keywords: elbasvir, grazoprevir, healthy volunteers, hepatitis C virus, pharmacokineticsLi HYang ZZhang SXu LWei YJiang JCaro LFeng HPMcCrea JBLi MXie SWang JZhao XMMu SDove Medical Pressarticleelbasvirgrazoprevirhealthy volunteershepatitis c viruspharmacokineticsTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 12, Pp 1-11 (2020)
institution DOAJ
collection DOAJ
language EN
topic elbasvir
grazoprevir
healthy volunteers
hepatitis c virus
pharmacokinetics
Therapeutics. Pharmacology
RM1-950
spellingShingle elbasvir
grazoprevir
healthy volunteers
hepatitis c virus
pharmacokinetics
Therapeutics. Pharmacology
RM1-950
Li H
Yang Z
Zhang S
Xu L
Wei Y
Jiang J
Caro L
Feng HP
McCrea JB
Li M
Xie S
Wang J
Zhao XM
Mu S
A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
description Haiyan Li,1 Zhenhua Yang,1 Shuang Zhang,1 Lin Xu,1 Yudong Wei,1 Jun Jiang,2 Luzelena Caro,3 Hwa-Ping Feng,3 Jacqueline B McCrea,3 Meng Li,2 Shuang Xie,2 Jiangdian Wang,2 Xu Min Zhao,2 Shengmei Mu2 1Drug Clinical Trial Center, Peking University Third Hospital, Beijing, People’s Republic of China; 2Department of Infectious Diseases, MSD (China) R&D, Beijing, People’s Republic of China; 3Department of Infectious Diseases, Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Haiyan LiDrug Clinical Trial Center, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing 100191, People’s Republic of ChinaTel +86 108 226 6226Email haiyanli1027@hotmail.comPurpose: The burden of hepatitis C virus infection is particularly high in Asian countries, and new treatments are urgently needed. The purpose of this study was to characterize the pharmacokinetics (PK) and safety of the fixed-dose combination tablet of elbasvir/grazoprevir in healthy Chinese participants.Patient and Methods: In this Phase I, single-site, open-label, 3-period study in healthy Chinese adults, participants received a single tablet of elbasvir 50 mg/grazoprevir 100 mg, followed by blood sampling for up to 96 hrs (http://www.chinadrugtrials.org.cn/ CTR20160034; Protocol PN071). Participants then received 1 tablet daily for 10 days, followed by a minimum 10-day washout, after which participants received a single dose of 2 tablets (elbasvir 100 mg/grazoprevir 200 mg). Elbasvir and grazoprevir PK were assessed following single and multiple doses. Safety and tolerability were also evaluated.Results: Twelve participants (50% male) were enrolled in and completed the study. Following single-dose oral administration of elbasvir 50 mg/grazoprevir 100 mg or elbasvir 100 mg/grazoprevir 200 mg, the median Tmax was 3– 4 hrs and elimination half-life was 18 hrs (elbasvir) and 30 hrs (grazoprevir). Multiple-dose administration resulted in AUC0– 24 accumulation ratios of 1.58 (elbasvir) and 2.35 (grazoprevir). Both elbasvir 50 mg/grazoprevir 100 mg and 100 mg/200 mg regimens were generally well tolerated.Conclusion: Single-dose administration of elbasvir 50 mg/grazoprevir 100 mg or 100 mg/200 mg and once-daily administration of elbasvir 50 mg/grazoprevir 100 mg for 10 days has been adequately characterized, with PK values within the expected range, and was generally well tolerated in healthy Chinese male and female participants.Keywords: elbasvir, grazoprevir, healthy volunteers, hepatitis C virus, pharmacokinetics
format article
author Li H
Yang Z
Zhang S
Xu L
Wei Y
Jiang J
Caro L
Feng HP
McCrea JB
Li M
Xie S
Wang J
Zhao XM
Mu S
author_facet Li H
Yang Z
Zhang S
Xu L
Wei Y
Jiang J
Caro L
Feng HP
McCrea JB
Li M
Xie S
Wang J
Zhao XM
Mu S
author_sort Li H
title A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
title_short A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
title_full A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
title_fullStr A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
title_full_unstemmed A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
title_sort single- and multiple-dose study to evaluate the pharmacokinetics of fixed-dose grazoprevir/elbasvir in healthy chinese participants
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/5ba2d1b73d934369bcea130b373ff7f2
work_keys_str_mv AT lih asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT yangz asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT zhangs asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT xul asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT weiy asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT jiangj asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT carol asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT fenghp asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT mccreajb asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT lim asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT xies asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT wangj asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT zhaoxm asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT mus asingleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT lih singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT yangz singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT zhangs singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT xul singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT weiy singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT jiangj singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT carol singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT fenghp singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT mccreajb singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT lim singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT xies singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT wangj singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT zhaoxm singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
AT mus singleandmultipledosestudytoevaluatethepharmacokineticsoffixeddosegrazoprevirelbasvirinhealthychineseparticipants
_version_ 1718394691606544384